Discovery of 3-Pyridyl Isoindolin-1-one Derivatives as Potent, Selective, and Orally Active Aldosterone Synthase (CYP11B2) Inhibitors.
Administration, Oral
Animals
Cytochrome P-450 CYP11B2
/ antagonists & inhibitors
Cytochrome P-450 Enzyme Inhibitors
/ administration & dosage
Drug Design
Drug Stability
Humans
Isoindoles
/ chemistry
Models, Molecular
Molecular Conformation
Pyridines
/ administration & dosage
Rats
Structure-Activity Relationship
Tissue Distribution
Journal
Journal of medicinal chemistry
ISSN: 1520-4804
Titre abrégé: J Med Chem
Pays: United States
ID NLM: 9716531
Informations de publication
Date de publication:
09 07 2020
09 07 2020
Historique:
pubmed:
13
6
2020
medline:
18
11
2020
entrez:
13
6
2020
Statut:
ppublish
Résumé
Aldosterone synthase (CYP11B2) inhibitors have been explored in recent years as an alternative therapeutic option to mineralocorticoid receptor (MR) antagonists to reduce elevated aldosterone levels, which are associated with deleterious effects on various organ systems including the heart, vasculature, kidney, and central nervous system (CNS). A benzamide pyridine hit derived from a focused screen was successfully developed into a series of potent and selective 3-pyridyl isoindolin-1-ones CYP11B2 inhibitors. Our systematic structure-activity relationship study enabled us to identify unique structural features that result in high selectivity against the closely homologous cortisol synthase (CYP11B1). We evaluated advanced lead molecules, exemplified by compound
Identifiants
pubmed: 32530624
doi: 10.1021/acs.jmedchem.0c00233
doi:
Substances chimiques
Cytochrome P-450 Enzyme Inhibitors
0
Isoindoles
0
Pyridines
0
Cytochrome P-450 CYP11B2
EC 1.14.15.4
pyridine
NH9L3PP67S
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM